Dr. Seth Wander is a medical oncologist at the Massachusetts General Hospital with a clinical and translational research interest in breast cancer and cancer genomics. Dr. Wander completed his undergraduate degree at Cornell University, where he studied Molecular and Cell Biology and graduated magna cum laude with distinction in research. He pursued his MD and PhD in Cancer Biology at the University of Miami, followed by residency training at the Massachusetts General Hospital and fellowship training at the Dana-Farber Cancer Institute. Dr. Wander's translational research program is focused upon genomic mechanisms of resistance to targeted therapies in metastatic breast cancer. Dr. Wander has published more than fifty peer-reviewed manuscripts related to the emerging field of precision medicine, and efforts to utilize genetic sequencing results to understand how cancers become resistant to standard therapies in order to develop novel treatment strategies. He is an assistant professor of medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows. He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 recipient of the Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award. Dr. Wander, as part of a multidisciplinary team, leads a variety of clinical trials focused on developing novel clinical strategies for patients with metastatic breast cancer and resistance to hormonal and targeted agents. He has presented educational sessions and original research both nationally and internationally related to drug resistance and the development of personalized treatments for breast cancer.